ScripDegron Therapeutics, a Chinese specialist in molecular glue degraders (MGD), is looking beyond technology-based, compound screening collaborations with multinational big pharmas. MGDs, an emerging dru
ScripTakeda Pharmaceutical and partner Protagonist Therapeutics are now awaiting 52-week data from their registrational trial of rusfertide in polycythemia vera (PV) patients dependent on phlebotomy, after
ScripThe 2025 American Society of Clinical Oncology conference will take place in Chicago from 30 May-3 June, and while it typically leans toward solid tumors, it also often features a number of important
ScripTakeda is looking forward to two new drug application filings later this year and multiple Phase III data readouts. The company also said it is expecting limited impacts from the Trump Administration’